Description

Compound:

Each tablet contains:

Metformin hydrochloride 1000 mg

Auxiliary components:

povidone K30, magnesium stearate.

Properties:

Metformin is a biguanide with a hypoglycemic effect, reducing both basal and postprandial plasma glucose levels. It does not stimulate insulin secretion and therefore does not cause hypoglycemia. Increases the sensitivity of peripheral receptors to insulin and the utilization of glucose by cells. Reduces liver glucose production by inhibiting gluconeogenesis and glycogenolysis. Delays the absorption of glucose in the intestine.

Metformin stimulates glycogen synthesis by acting on glycogen synthase. Increases the transport capacity of all types of membrane glucose transporters.

While taking metformin, the patient’s body weight either remains stable or decreases moderately.

Metformin has a beneficial effect on lipid metabolism: it reduces total cholesterol, LDL and triglycerides

Indications:

Type 2 diabetes mellitus, especially in obese patients, with the ineffectiveness of diet therapy and exercise in adults as monotherapy or in combination with other oral hypoglycemic drugs, or with insulin.

Directions for use and dosage:

Take orally.

The tablets are swallowed whole, without chewing, with a sufficient amount of liquid, 1 time per day during or after dinner.

The dose of Glucophage XR 1000 mg is selected by the doctor individually for each patient based on the results of measuring the concentration of glucose in the blood.

The maximum recommended dose of Glucophage XR 1000 mg is 2 tablets per day (2000 mg). If adequate glycemic control cannot be achieved when taking the maximum recommended dose once a day, the maximum dose can be divided into two doses: 1 1000 mg tablet with breakfast and 1 1000 mg tablet with dinner. If adequate glycemic control is not achieved in this case, a switch to regular-release metformin (for example, Glucophage film-coated tablets) with a maximum daily dose of 3000 mg is possible.

Contraindications:

– hypersensitivity to metformin or to any excipient;

-diabetic ketoacidosis, diabetic precoma, coma;

-renal failure or impaired renal function (creatinine clearance less than 45 ml/min);

-acute conditions that occur with a risk of developing renal dysfunction:

-dehydration (with diarrhea, vomiting), severe infectious diseases, shock;

-clinical pronounced manifestations of acute or chronic diseases that can lead to the development of tissue hypoxia;

-extensive surgical operations and injuries;

– liver failure, liver dysfunction;

-chronic alcoholism, acute alcohol poisoning;

-pregnancy;

-lactic acidosis;

– use for a period of less than 48 hours before and within 48 hours after radioisotope or x-ray studies with the introduction of an iodine-containing contrast agent;

-compliance with a hypocaloric diet (<1000 kcal/day); -children under 18 years of age due to the lack of data on use. Precautionary measures:

Lactic acidosis is a rare but serious (high mortality unless promptly treated) complication that may occur due to accumulation of metformin. Cases of lactic acidosis when taking metformin occurred mainly in diabetic patients with severe renal failure.
Side effects:

Gastrointestinal disorders:

Very often – nausea, vomiting, diarrhea, abdominal pain, lack of appetite. Most often they occur during the initial period of treatment and in most cases resolve spontaneously.

Disorders of the skin and subcutaneous tissues:

Very rarely – skin reactions such as erythema, itching, rash.

Disorders of the liver and biliary tract:

Very rarely – abnormal liver function tests and hepatitis; after discontinuation of metformin, these adverse effects completely disappear.

Storage method:

Store at a temperature not exceeding 30 degrees.